Robyn Karnauskas
Stock Analyst at Truist Securities
(2.47)
# 2,234
Out of 4,778 analysts
182
Total ratings
43.05%
Success rate
-0.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Hold | $333 → $298 | $314.38 | -5.21% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $61.05 | +6.47% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $92.31 | +19.16% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $106.74 | -22.24% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $209.17 | +0.40% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $2.79 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $141.60 | +140.11% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $2.60 | +900.00% | 2 | May 15, 2024 | |
| CHRS Coherus BioSciences | Maintains: Buy | $8 → $7 | $0.95 | +635.29% | 13 | May 13, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,135 | $661.00 | +71.71% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $2.54 | +293.70% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $3.10 | +190.32% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $17.61 | +320.22% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $10.83 | +112.37% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $19.44 | +146.91% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $9.12 | +448.25% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $864.90 | -1.72% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $511.74 | -0.73% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $26.14 | +37.72% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $57.03 | -56.16% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.29 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $71.99 | +94.47% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $0.79 | +18,887.34% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $0.94 | +644.68% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $14.77 | +272.38% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.35 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $2.59 | +1,019.69% | 1 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $19.51 | +1,540.18% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $3.52 | +326.14% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.56 | +15,086.71% | 1 | Oct 8, 2020 |
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $314.38
Upside: -5.21%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $61.05
Upside: +6.47%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $92.31
Upside: +19.16%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $106.74
Upside: -22.24%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $209.17
Upside: +0.40%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.79
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $141.60
Upside: +140.11%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $2.60
Upside: +900.00%
Coherus BioSciences
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.95
Upside: +635.29%
Regeneron Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $661.00
Upside: +71.71%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $2.54
Upside: +293.70%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $3.10
Upside: +190.32%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $17.61
Upside: +320.22%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $10.83
Upside: +112.37%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $19.44
Upside: +146.91%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $9.12
Upside: +448.25%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $864.90
Upside: -1.72%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $511.74
Upside: -0.73%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $26.14
Upside: +37.72%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $57.03
Upside: -56.16%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.29
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $71.99
Upside: +94.47%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $0.79
Upside: +18,887.34%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $0.94
Upside: +644.68%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $14.77
Upside: +272.38%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.35
Upside: -
Nov 16, 2022
Initiates: Buy
Price Target: $29
Current: $2.59
Upside: +1,019.69%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $19.51
Upside: +1,540.18%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $3.52
Upside: +326.14%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.56
Upside: +15,086.71%